
via IBM Research
Antibiotic resistance is no joke. It’s a huge threat to human health — even more so during the raging pandemic. We need new antibiotics, and we need them fast.
In the US alone, nearly three million people¹ get infected with antibiotic-resistant bacteria or fungi every year¹. But very few new antibiotics are being developed to replace those that no longer work. That’s because drug design is an extremely difficult and lengthy process — there are more possible chemical combinations of a new molecule than there are atoms in the Universe.
We want to help.
Paving the way to the era of Accelerated Discovery, our IBM Research team has developed an AI system that can help speed up the design of molecules for novel antibiotics. And it works — in “Accelerating Antimicrobial Discovery with Controllable Deep Generative Models and Molecular Dynamics,” published in Nature Biomedical Engineering, we outline how we used it to create two new non-toxic antimicrobial peptides (AMPs) with strong broad-spectrum potency. Peptides are small molecules — they are short strings of amino acids, the building blocks of proteins. Our approach outperforms other leading de novo AMP design methods by nearly 10 percent.
Beyond antibiotics, this generative AI system could potentially accelerate the design process of the best possible molecules for new drugs and materials — helping scientists to use AI to discover and design better candidates for more effective drugs and therapies for diseases, materials to absorb and capture carbon to help fight climate change, materials for more intelligent energy production and storage, and much more. To fight these challenges, we need to accelerate the rate of discovery of new and functional molecules — at scale.
Where is that molecule?
That’s far from easy. Zeroing in on the correct molecular configuration that would lead to a new material with desired properties among the astronomical number of possible molecules is like looking for a needle in a haystack. For peptides, one would typically have to experimentally screen more than a hundred molecules to find one with the right properties.
So we’ve turned to AI for help.
First, we used an AI generative model dubbed a deep generative autoencoder to learn about the vast space of known peptide molecules. The model captured meaningful information such as molecular similarity and function about diverse peptide sequences, enabling us to explore beyond known antimicrobial templates.
We then applied Controlled Latent attribute Space Sampling (CLaSS) — a recently developed computational method for generating novel peptide molecules with custom properties. It works by sampling from the informative latent space of peptides and relies on a rejection sampling scheme guided by the molecular property the classifier trained on during the latent representation. Since CLaSS performs attribute-conditioned sampling in the compressed latent space, it is a computationally efficient and scalable approach that can be easily repurposed.
We then used deep learning classifiers to screen the AI-generated candidate antimicrobial molecules for additional key attributes, such as toxicity and broad-spectrum activity. We performed additional screening with the help of high-throughput, coarse-grained molecular dynamics simulations. These simulations look for presence of novel physicochemical features indicative of stable and peptide-membrane binding, such as low-contact variance between peptide and membrane.
Within 48 days, our AI-boosted molecular design approach to Accelerated Discovery enabled us to identify, synthesize, and experimentally test 20 AI-generated novel candidate antimicrobial peptides. Two of them turned out to be highly potent against diverse Gram-positive and Gram-negative pathogens (including multidrug-resistant K. pneumoniae) and very unlikely to trigger drug resistance in E. coli.
We also didn’t find any cross-resistance for either of the AMPs when tested using a polymyxin-resistant strain. Live-cell confocal imaging showed the formation of membrane pores as the underlying mechanism of bactericidal mode of action of these peptides. Both antimicrobials have low toxicity — we tested them in vitro and also in mice, providing important information about the safety, toxicity and efficacy of these antimicrobial candidates in a complex animal model.
Our proposed approach could potentially lead to faster and more efficient discovery of potent and selective broad-spectrum antimicrobials to keep antibiotic-resistant bacteria at bay — for good. And we hope that our AI could also be used to help address the world’s other most difficult discovery challenges, such as designing new therapeutics, environmentally friendly and sustainable photoresists, new catalysts for more efficient carbon capture, and so much more.
Original Article: IBM AI finds new peptides – paving the way to better drug design
More from: IBM Research
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
New antibiotics
- Buy Antibiotics Online - Over The Counter
Antibiotics are drugs that are used to treat infections caused by bacteria. There are a variety of antibiotics, but they can be divided into six groups.
- A protein structure reveals how replication of DNA coding for antibiotic resistance is initiated
In all living organisms, DNA replication is essential to ensure the genetic fidelity of the next generation. However, bacteria can also transfer genetic information horizontally to other bacteria.
- There is really nothing super about Antibiotic Resistant Gonorrhea
Reports out of Massachusetts are raising concerns of a highly resistant strain of gonorrhea being seen for the first time in the United States. Are we close to living in a reality where there are no m ...
- Lunaemycin, a new antibiotic extracted from moonmilk deposits
"Statistically, it's as if all you have to do is bend over and pick up and identify a new antibiotic, antifungal or even anticancer agents," says the researcher. The reality is obviously much more ...
- Antibiotics Market Projected to Reach US$ 59,253.24 Million by 2028
The Insight Partners Latest Research for Report "Antibiotics Market Forecast to 2028" Focuses COVID-19 Impact and Global Analysis By Drug Class ...
Go deeper with Google Headlines on:
New antibiotics
[google_news title=”” keyword=”new antibiotics” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antibiotic development
- Up to 56% of adults have received inappropriate antibiotics for bacterial infections: study
Up to 56 percent of U.S. adults received inappropriate antibiotics for common bacterial respiratory infections between 2016 and 2018, according to findings from researchers at Washington University in ...
- A protein structure reveals how replication of DNA coding for antibiotic resistance is initiated
In all living organisms, DNA replication is essential to ensure the genetic fidelity of the next generation. However, bacteria can also transfer genetic information horizontally to other bacteria.
- Lessons Learned in 2022 and the Impact on Drug Development in the Year Ahead
Drawing insights from industry news and the findings of a survey of over 150 biopharma and biotech leaders conducted by the PPD clinical research business of Thermo Fisher Scientific, the following ...
- Novartis confirms it has stopped development of experimental Huntington’s drug
Termination of the branaplam program, according to Novartis, was due to an “overall assessment of the risk-benefit profile” observed in a mid-stage clinical trial that raised safety concerns last year ...
- NIH grant funds research on a powerful new approach to drug development
A new NIH MIRA grant funds biochemist Scott Lokey’s efforts to develop complex, membrane-permeable molecules as next-generation therapeutic agents.
Go deeper with Google Headlines on:
Antibiotic development
[google_news title=”” keyword=”antibiotic development” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]










